BioNTech cuts sales

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech reduced its 2026 revenue guidance to €1.6-1.9 billion due to softening COVID vaccine demand, with Q2 revenue falling over 50%. The German pharma company also appointed a new CEO and plans to